预约演示
更新于：2025-08-06
Olopatadine Hydrochloride
盐酸奥洛他定
更新于：2025-08-06
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1996-12-18), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H24ClNO3 |
InChIKeyHVRLZEKDTUEKQH-NOILCQHBSA-N |
CAS号140462-76-6 |
关联
86
项与 盐酸奥洛他定 相关的临床试验CTR20252205
盐酸奥洛他定片人体生物等效性研究
CTRI/2025/04/085610
Randomized Controlled Clinical Trial on Comparison of Yastimadhu Arka Eye Drop with Olopatadine 0.1% Eye Drop in Vataj Abhishyanda (Simple Allergic Conjunctivitis)
CTR20250961
盐酸奥洛他定颗粒在空腹条件下的人体生物等效性试验
100 项与 盐酸奥洛他定 相关的临床结果
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的转化医学
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的专利（医药）
登录后查看更多信息
758
项与 盐酸奥洛他定 相关的文献（医药）2025-09-01EUROPEAN JOURNAL OF PHARMACOLOGY
Drug-related visual blurring: findings from the U.S. Food and Drug Administration Adverse Event Reporting System database
Article
作者: Chen, Lin ; Liu, Zuguo ; Wu, Shi-Nan ; Guan, Wen-Ying ; Hu, Jiaoyue ; Sun, Le ; Huang, Caihong ; Chen, Xiao-Dong ; Liu, Qian-Ting ; Kang, Jia-Yu
BACKGROUND:
Visual blurring is one of the most common symptoms in ophthalmology, and one of the important causes of secondary visual blurring is drug-related. This study assesses the risk of drug-related visual blurring using a large real-world database.
METHODS:
We analyzed adverse event reports from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database between January 2004 and September 2024. Disproportionality analysis algorithm were used. Drugs related with positive signals for visual blurring were categorized, and the risk levels, number of reports, and drug-induced onset times were quantified.
RESULTS:
Disproportionality analysis of the FAERS database identified 119 drugs with positive signals for visual blurring, primarily in the following categories: ophthalmic medications (Lifitegrast, Reporting Odds Ratio [ROR] = 53.24; 95 % Confidence Interval [CI]: 49.19-57.61), endocrine medications (Semaglutide, ROR = 3.26 [2.84-3.75]), nervous system medications (Pregabalin, ROR = 4.15 [3.93-4.37]), oncology medications (Encorafenib, ROR = 5.38 [4.37-6.62]), antimuscarinic medications (Fesoterodine, ROR = 6.77 [5.08-9.03]), and other medications (Dupilumab, ROR = 8.39 [8.16-8.64]). The top three drugs associated with the highest incidence of blurred vision as an adverse event are lifitegrast, oxymetazoline, and olopatadine. Antimuscarinic Medications had the shortest drug-induced onset time. Women (63.87 %) and middle-aged to elderly individuals [Age (mean ± standard deviation): 53.59 ± 18.79] were the main populations affected by drug-related visual blurring.
CONCLUSION:
Preventing drug-related vision issues is vital. Early risk assessment and intervention with personalized medication can reduce side effects, ensure safety, and improve quality of life.
2025-07-01Ocular Surface
Ranking the efficacy of topical treatments for ocular allergy: A network meta-analysis of current evidence
Review
作者: Krungkraipetch, Dechathorn ; Tansavadi, Taweelarp ; Krungkraipetch, Luksanaporn
PURPOSE:
To evaluate and rank the comparative effectiveness of topical treatments for different types of ocular allergies through a systematic review and network meta-analysis.
METHODS:
A systematic search of electronic databases identified between January 2000 and December 2024 from PubMed, Cochrane CENTRAL, Google Scholar, and Scopus databases. Study Selection; randomized controlled trials assessing topical treatments for ocular allergy, including antihistamines, corticosteroids, immunomodulators, and combination therapies. Data Extraction and Synthesis; data were independently extracted and analyzed following PRISMA guidelines. Direct and indirect comparisons were evaluated using network meta-analysis, and SUCRA rankings assessed relative efficacy. Main Outcomes and Measures; reduction in ocular itching, redness, and inflammation. PROSPERO Registration number: CRD42025634572.
RESULTS:
Olopatadine 0.1 % demonstrated highest efficacy in seasonal and perennial allergic conjunctivitis (SUCRA 0.88 and 0.85, respectively), while Tacrolimus 0.1 % showed superior effectiveness in vernal and atopic keratoconjunctivitis (SUCRA 0.92 and 0.89, respectively). Overall treatment effect was significant (OR = 6.95, 95 % CI: 6.24-7.75) with moderate heterogeneity (I2 = 50.8 %). Subgroup analysis revealed consistent efficacy across different types of allergic conjunctivitis, with seasonal allergic conjunctivitis showing the highest cumulative ranking probability (89.0 %).
CONCLUSIONS:
This network meta-analysis provides strong evidence supporting condition-specific treatment approaches in ocular allergies. Newer antihistamines, particularly Olopatadine, are most effective for mild-moderate conditions, while immunomodulators, especially Tacrolimus, show superior efficacy in severe cases. These findings provide clear evidence-based hierarchies for clinical decision-making in the management of different types of allergic conjunctivitis.
2025-04-01INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Association between congenital Zika syndrome and hospitalizations during early childhood: a nationwide cohort study
Article
作者: Teixeira, Maria Gloria ; Paixão, Enny S ; Barreto, Mauricio L ; Tedde, João Guilherme G ; Costa, Maria da Conceição ; Cardim, Luciana ; Silva, Thiago Cerqueira ; Brickley, Elizabeth B ; Rodrigues, Laura
OBJECTIVES:
Congenital Zika Syndrome (CZS) has been linked to a wide spectrum of abnormalities. However, differences in hospitalization patterns between children with and without CZS have not yet been investigated.
METHODS:
We compared rates of hospital admissions for all and specific diseases, proportions of admission causes, and total length of hospital stay (LOS) between children with CZS and those without the syndrome. Adjusted incidence rate ratios (aIRR) and aLOS were estimated using negative binomial regression.
RESULTS:
Compared to those without CZS, the aIRR for all-cause hospitalizations in the CZS group ranged from 3.77 (95%CI: 3.47-4.06) in the neonatal period to 7.76 (95%CI: 6.91-8.61) at ages 2-4 years. Similar trends were observed for specific causes of admissions. Most admissions in the CZS group related to congenital malformations, neurological, respiratory and infectious diseases. aLOS ranged from 16.0 days [95%CI: 13.2-19.5] to 19.9 days among CZS patients and 6.0 days [95%CI: 5.9-6.2] to 9.3 days [95%CI: 9.3-9.4] for patients without the syndrome.
CONCLUSION:
Children born with CZS face significantly higher rates of hospitalization and longer stays compared to those without the syndrome during early childhood.
100 项与 盐酸奥洛他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2008-04-15 | |
| 过敏性鼻结膜炎 | 日本 | 2006-07-26 | |
| 季节性过敏性结膜炎 | 欧盟 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 澳大利亚 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 冰岛 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 列支敦士登 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 挪威 | 2002-05-16 | |
| 瘙痒 | 日本 | 2000-12-22 | |
| 过敏性鼻炎 | 日本 | 2000-12-22 | |
| 荨麻疹 | 日本 | 2000-12-22 | |
| 变应性结膜炎 | 美国 | 1996-12-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 常年过敏性结膜炎 | 临床3期 | - | 2012-01-01 | |
| 急性结膜炎 | 临床3期 | - | 2009-10-01 | |
| 常年性变应性鼻炎 | 临床3期 | 美国 | 2006-12-01 | |
| 鼻结膜炎 | 临床3期 | - | 2006-04-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 96 | 糧繭襯繭遞範蓋餘製觸(艱衊衊顧淵衊淵鏇鏇鬱) = 艱鬱鬱簾鹽顧憲齋鬱淵 鬱糧艱衊糧醖襯鹹餘衊 (願鑰糧淵壓願醖簾醖醖 ) | 积极 | 2019-03-06 | |||
Sodium Cromoglycate 2% | 糧繭襯繭遞範蓋餘製觸(艱衊衊顧淵衊淵鏇鏇鬱) = 夢簾顧選憲選夢獵餘衊 鬱糧艱衊糧醖襯鹹餘衊 (願鑰糧淵壓願醖簾醖醖 ) | ||||||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 淵鏇襯簾鬱憲壓夢範簾(簾築鹹網築遞夢構鬱願) = 窪願糧製衊觸憲願鏇壓 網廠繭觸淵壓壓蓋衊齋 (衊遞鏇構觸選築壓願衊, -0.41 ~ -0.05) | - | 2019-02-01 | ||
N/A | 21 | 遞衊醖窪網願觸觸簾繭(範鏇積鏇壓製鹽積膚糧) = 餘構觸願築夢醖獵獵餘 夢糧鏇廠顧觸遞選獵鹽 (簾蓋顧壓願憲簾壓鹹願, 窪鹽繭範衊廠憲製網觸 ~ 鹽窪鑰鏇膚鬱衊鬱製觸) 更多 | - | 2018-09-20 | |||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 夢繭蓋鑰夢網獵願淵觸(餘積選顧衊網網襯願醖) = 鬱襯獵餘顧繭壓範鏇鬱 顧製齋廠蓋壓願鬱鬱簾 (衊膚艱壓艱鹽鏇顧夢鏇, -0.35[-0.63 ~ -0.07]) | - | 2018-02-01 | ||
临床3期 | - | 448 | Olopatadine 0.77% | 鬱壓鹹選遞衊選鏇構衊(築網選鏇製簾鬱襯壓鹽) = 窪繭簾製製獵鬱積餘遞 製鹹顧構鹽夢衊繭選壓 (餘窪醖膚艱遞鹹鏇齋廠 ) | 积极 | 2015-06-01 | |
Olopatadine 0.1% | 鬱壓鹹選遞衊選鏇構衊(築網選鏇製簾鬱襯壓鹽) = 憲遞窪鏇築醖窪廠獵積 製鹹顧構鹽夢衊繭選壓 (餘窪醖膚艱遞鹹鏇齋廠 ) | ||||||
临床4期 | 17 | (Left Eye) | 糧衊淵鏇壓鹹憲齋繭膚(製蓋鏇膚顧積鹹觸鑰壓) = 選範襯衊鬱觸顧艱積艱 壓簾鑰鹹鏇齋糧糧夢選 (齋艱顧憲憲鬱簾齋鹽窪, 0.85) 更多 | - | 2014-08-18 | ||
(Right Eye) | 糧衊淵鏇壓鹹憲齋繭膚(製蓋鏇膚顧積鹹觸鑰壓) = 蓋醖網觸廠網廠憲憲鬱 壓簾鑰鹹鏇齋糧糧夢選 (齋艱顧憲憲鬱簾齋鹽窪, 0.92) 更多 | ||||||
临床3期 | 902 | (AL-4943A) | 艱觸構憲願襯窪選窪範(廠衊糧顧遞構鏇蓋壓願) = 範鬱蓋獵糧衊夢糧齋獵 網選繭夢構鑰蓋餘糧簾 (鹹範顧鏇衊壓獵遞艱顧, 0.069) 更多 | - | 2014-08-11 | ||
艱觸構憲願襯窪選窪範(廠衊糧顧遞構鏇蓋壓願) = 艱廠觸淵鹹遞範簾餘積 網選繭夢構鑰蓋餘糧簾 (鹹範顧鏇衊壓獵遞艱顧, 0.069) 更多 | |||||||
临床3期 | 518 | (AL-4943A) | 壓淵獵遞糧網餘夢壓網 = 積製簾膚構壓網齋積獵 窪夢網壓襯製糧鏇製鹹 (淵蓋顧鹹齋觸壓範觸襯, 繭齋願網淵遞構鏇鬱廠 ~ 醖憲範繭鑰蓋選醖窪築) 更多 | - | 2014-02-28 | ||
(AL-4943A Vehicle) | 壓淵獵遞糧網餘夢壓網 = 糧獵衊製蓋製艱衊蓋鹽 窪夢網壓襯製糧鏇製鹹 (淵蓋顧鹹齋觸壓範觸襯, 醖艱獵鬱鹹製鹽積顧襯 ~ 顧選鬱鹹膚窪獵顧壓衊) 更多 | ||||||
临床4期 | 157 | (Lastacaft®) | 願鹽壓膚襯鏇鏇構憲積(積選夢鏇壓鏇餘壓選壓) = 積憲顧糧餘憲獵顧範壓 膚顧艱鑰淵鹽襯獵齋窪 (憲窪選窪遞觸鹹壓鬱餘, 0.582) 更多 | - | 2014-01-14 | ||
(Pataday™) | 願鹽壓膚襯鏇鏇構憲積(積選夢鏇壓鏇餘壓選壓) = 築鑰淵鏇醖壓壓齋積夢 膚顧艱鑰淵鹽襯獵齋窪 (憲窪選窪遞觸鹹壓鬱餘, 0.752) 更多 | ||||||
临床3期 | 397 | (AL-4943A) | 願簾獵構選鑰艱鑰繭製(範鑰艱齋範構餘襯衊淵) = 襯構襯構鬱選積蓋鹽顧 獵鬱觸蓋衊廠繭齋範蓋 (衊顧願獵鏇膚膚簾襯構, 0.7) 更多 | - | 2013-05-23 | ||
(Vehicle) | 願簾獵構選鑰艱鑰繭製(範鑰艱齋範構餘襯衊淵) = 廠鬱鏇願艱構獵鬱憲鏇 獵鬱觸蓋衊廠繭齋範蓋 (衊顧願獵鏇膚膚簾襯構, 1.1) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用